GLI2 Orchestrates Tumor Immune Evasion via WNT and Prostaglandin Pathways

Study Background and Research Question

Immune checkpoint blockade (ICB), particularly anti-PD-1 therapy, has transformed cancer treatment by providing durable responses in various malignancies. Yet, both primary and adaptive resistance to ICB remain major obstacles, with mesenchymal transformation (MT) frequently implicated in immune evasion and therapeutic failure. Despite prior associations between MT and immunotherapy resistance, the precise molecular mediators enabling tumors to circumvent immune attack have remained elusive. DeVito et al. (2025) investigated the hypothesis that the Hedgehog pathway transcription factor GLI2 acts as a pivotal regulator of tumor immune evasion, coordinating downstream signaling to modulate the tumor microenvironment and resistance to immunotherapy (DeVito et al., 2025).

Key Innovation from the Reference Study

The study's central innovation lies in identifying GLI2 as a nodal transcriptional regulator mediating immunosuppressive reprogramming during mesenchymal transformation. Specifically, GLI2 upregulates both WNT ligand production and prostaglandin synthesis within tumor cells, thereby fostering a microenvironment that impairs antitumor immunity and facilitates resistance to anti-PD-1 therapy. This mechanistic insight delineates a direct link between the Hedgehog signaling pathway’s distal effectors (GLI transcription factors) and immune modulation in the tumor microenvironment, offering a new translational target for combination immunotherapies (DeVito et al., 2025).

Methods and Experimental Design Insights

DeVito et al. employed a multifaceted approach, combining autochthonous mouse tumor models, in vitro transcriptional profiling, and analysis of clinical datasets from stage IV melanoma patients. The study utilized genetic and pharmacological perturbations of GLI2 activity to elucidate its role in orchestrating downstream signaling. Key experimental strategies included:

• Genetic overexpression and knockdown of GLI2 in tumor cells to assess changes in WNT ligand and prostaglandin pathway gene expression.
• Pharmacological inhibition of EP2/EP4 prostaglandin receptors and WNT ligand secretion to dissect their relevance in immune evasion and ICB resistance.
• Flow cytometry and immunohistochemistry to characterize immune cell composition and function within the tumor microenvironment.
• Patient dataset analysis linking a GLI2 transcriptional signature to clinical outcomes under anti-PD-1 therapy.

This integrative methodology enabled the authors to connect molecular mechanisms to functional immune consequences in both experimental models and human disease (DeVito et al., 2025).

Core Findings and Why They Matter

The principal findings are as follows:

• GLI2 activation upregulates WNT ligands and prostaglandin synthesis: Tumors with elevated GLI2 expression show increased production of immunomodulatory WNT ligands and prostaglandins, which in turn shape the tumor microenvironment.
• Recruitment of granulocytic myeloid-derived suppressor cells (PMN-MDSCs): These factors drive the accumulation and function of PMN-MDSCs, potent immunosuppressive cells that dampen antitumor T cell responses and promote tumor progression.
• Suppression of dendritic, CD8+ T, and NK cells: Elevated GLI2 signaling impairs the viability and function of type I conventional dendritic cells (cDC1), CD8+ cytotoxic T cells, and natural killer (NK) cells within the tumor, directly undermining immune-mediated tumor clearance.
• Pharmacologic targeting reverses immunosuppression and resistance: Inhibition of EP2/EP4 receptors or WNT secretion partially restores immune cell function and prevents both primary and adaptive resistance to anti-PD-1 therapy in preclinical models.
• Clinical correlation in melanoma: A GLI2-dependent gene expression signature correlates with resistance to anti-PD-1 therapy in patients with advanced melanoma, underscoring translational relevance (DeVito et al., 2025).

Collectively, these results reveal new mechanistic underpinnings for immune evasion and suggest that GLI2 represents a promising target for combination immunotherapy regimens in cancers exhibiting mesenchymal plasticity and Hedgehog pathway activation.

Comparison with Existing Internal Articles

Several recent internal resources have explored the role of GLI inhibitors—particularly GANT61—in dissecting the downstream effects of Hedgehog signaling in cancer research. For instance, the article “GANT61: Selective GLI Inhibitor for Hedgehog Pathway Research” emphasizes the use of GANT61 in modeling GLI-mediated transcriptional programs and its utility in preclinical cancer models. Similarly, “Targeting the Distal Hedgehog Pathway: GANT61 as a Strategy” provides a strategic overview of translational research targeting GLI1/2 to overcome therapy resistance. These resources contextualize the DeVito et al. findings by highlighting the importance of selective GLI antagonists in probing the intersection of Hedgehog pathway activity, immune modulation, and therapeutic resistance. Notably, GANT61 has been established as a robust tool for inhibiting GLI-mediated transcription and evaluating downstream immunosuppressive mechanisms in tumor models (source: internal_article).

Protocol Parameters

• GLI-mediated transcriptional inhibition assay | IC50 ≈ 5 μM | in vitro cancer cell lines | Validates specificity and potency of GLI inhibition | product_spec
• Tumor growth suppression in xenograft models | 50 mg/kg (i.p. or s.c.) | neuroblastoma, rhabdomyosarcoma | Demonstrates in vivo efficacy and dosing feasibility | product_spec
• Cell cycle arrest measurement | G0/G1 phase analysis | GLI-driven cancer models | Confirms mechanistic effect of GLI inhibition | workflow_recommendation
• Immune cell infiltration quantification | flow cytometry, IHC | Tumor immunology studies | Links GLI inhibition to immune microenvironment changes | workflow_recommendation

Limitations and Transferability

While DeVito et al. provide compelling preclinical and translational evidence, several limitations should be considered. First, the study's mechanistic insights derive primarily from murine models and correlative human gene expression analyses; functional validation in additional human cancer types and clinical settings is warranted. Second, the complexity of tumor immune interactions means that targeting GLI2, WNT, or prostaglandin pathways may yield variable outcomes depending on tumor context, immune landscape, and existing therapy regimens. Finally, the relative contributions of canonical versus non-canonical Hedgehog pathway activation to GLI2-driven immune evasion require further dissection (DeVito et al., 2025).

Research Support Resources

Researchers seeking to replicate or extend these findings can leverage GANT61 (SKU A1615), a selective small-molecule GLI inhibitor, to dissect GLI-mediated transcription and its effects on tumor immune evasion and therapy resistance in preclinical models (source: product_spec). GANT61 is widely utilized for studying Hedgehog pathway inhibition, tumor growth suppression, and immune modulation, and can be integrated into protocols targeting GLI1/2-driven oncogenic processes. For additional experimental strategies and troubleshooting guidance, see the protocol-focused resource “GANT61 GLI Inhibitor: Workflows for Tumor Growth Suppression”.